EGFR inhibitor | sciencenewsnet.in

Breaking News

Beyond Higher Temperatures: Preparing for National Security Risks Posed by Climate Change

Extracting High-Purity Gold from Electrical and Electronic Waste

Innovation Tri-Valley Leadership Group and the Hertz Foundation Announce Partnership to Celebrate World-Class Talent

AANA Presents Excellence in State Government Relations Advocacy Award to Georgia

Being treated by a female physician associated with lower risk for death

Firearm violence risk score may help tailor, disseminate prevention efforts in emergency departments

ACP recommends an evidence-based public health approach to excessive alcohol use

System-level factors influence doctors to reduce low-value care practices

Treatment from female doctors leads to lower mortality and hospital readmission rates

Historical redlining associated with higher rate of firearm fatalities

23 Apr, 2024

AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer

April 8, 2024 sarah JonasResearch Results

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer

January 19, 2023 sarah JonasAnnouncement

MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.